KRAS and neoplasm: Published studies of pERK1/2 immunohistochemistry that used colorectal carcinoma biopsies (which do not suffer the technical limitations incurred in resections) have shown that, regardless of K-Ras or B-Raf mutation, tumour cell nuclei are clearly immunopositive in 72.2% [7].